Vessel bioengineering - Development of small-diameter arterial grafts -

Shuhei Tara, Kevin A. Rocco, Narutoshi Hibino, Tadahisa Sugiura, Hirotsugu Kurobe, Christopher K. Breuer, Toshiharu Shinoka

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

The development of vascular bioengineering has led to a variety of novel treatment strategies for patients with cardiovascular isease. Notably, combining biodegradable scaffolds with autologous cell seeding to create tissue-engineered ascular grafts (TEVG) allows for in situ formation of organized neovascular tissue and we have demonstrated he clinical viability of this technique in patients with congenital heart defects. The role of the scaffold is to rovide a temporary 3-dimensional structure for cells, but applying TEVG strategy to the arterial system requires caffolds that can also endure arterial pressure. Both biodegradable synthetic polymers and extracellular matrixbased atural materials can be used to generate arterial scaffolds that satisfy these requirements. Furthermore, the ole of specific cell types in tissue remodeling is crucial and as a result many different cell sources, from matured omatic cells to stem cells, are now used in a variety of arterial TEVG techniques. However, despite great progress n the field over the past decade, clinical effectiveness of small-diameter arterial TEVG (<6 mm) has remained elusive. o achieve successful translation of this complex multidisciplinary technology to the clinic, active participation f biologists, engineers, and clinicians is required.

Original languageEnglish (US)
Pages (from-to)12-19
Number of pages8
JournalCirculation Journal
Volume78
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Bioengineering
Transplants
Congenital Heart Defects
Blood Vessels
Arterial Pressure
Polymers
Stem Cells
Technology

Keywords

  • Cell seeding
  • Coronary artery disease
  • Scaffolds
  • Small-diameter arterial grafts
  • Tissue-engineered vascular grafts

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Tara, S., Rocco, K. A., Hibino, N., Sugiura, T., Kurobe, H., Breuer, C. K., & Shinoka, T. (2014). Vessel bioengineering - Development of small-diameter arterial grafts -. Circulation Journal, 78(1), 12-19. https://doi.org/10.1253/circj.CJ-13-1440

Vessel bioengineering - Development of small-diameter arterial grafts -. / Tara, Shuhei; Rocco, Kevin A.; Hibino, Narutoshi; Sugiura, Tadahisa; Kurobe, Hirotsugu; Breuer, Christopher K.; Shinoka, Toshiharu.

In: Circulation Journal, Vol. 78, No. 1, 01.01.2014, p. 12-19.

Research output: Contribution to journalReview article

Tara, S, Rocco, KA, Hibino, N, Sugiura, T, Kurobe, H, Breuer, CK & Shinoka, T 2014, 'Vessel bioengineering - Development of small-diameter arterial grafts -', Circulation Journal, vol. 78, no. 1, pp. 12-19. https://doi.org/10.1253/circj.CJ-13-1440
Tara, Shuhei ; Rocco, Kevin A. ; Hibino, Narutoshi ; Sugiura, Tadahisa ; Kurobe, Hirotsugu ; Breuer, Christopher K. ; Shinoka, Toshiharu. / Vessel bioengineering - Development of small-diameter arterial grafts -. In: Circulation Journal. 2014 ; Vol. 78, No. 1. pp. 12-19.
@article{d693f1ca6bf34f98b54e5b699aca2ac7,
title = "Vessel bioengineering - Development of small-diameter arterial grafts -",
abstract = "The development of vascular bioengineering has led to a variety of novel treatment strategies for patients with cardiovascular isease. Notably, combining biodegradable scaffolds with autologous cell seeding to create tissue-engineered ascular grafts (TEVG) allows for in situ formation of organized neovascular tissue and we have demonstrated he clinical viability of this technique in patients with congenital heart defects. The role of the scaffold is to rovide a temporary 3-dimensional structure for cells, but applying TEVG strategy to the arterial system requires caffolds that can also endure arterial pressure. Both biodegradable synthetic polymers and extracellular matrixbased atural materials can be used to generate arterial scaffolds that satisfy these requirements. Furthermore, the ole of specific cell types in tissue remodeling is crucial and as a result many different cell sources, from matured omatic cells to stem cells, are now used in a variety of arterial TEVG techniques. However, despite great progress n the field over the past decade, clinical effectiveness of small-diameter arterial TEVG (<6 mm) has remained elusive. o achieve successful translation of this complex multidisciplinary technology to the clinic, active participation f biologists, engineers, and clinicians is required.",
keywords = "Cell seeding, Coronary artery disease, Scaffolds, Small-diameter arterial grafts, Tissue-engineered vascular grafts",
author = "Shuhei Tara and Rocco, {Kevin A.} and Narutoshi Hibino and Tadahisa Sugiura and Hirotsugu Kurobe and Breuer, {Christopher K.} and Toshiharu Shinoka",
year = "2014",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-13-1440",
language = "English (US)",
volume = "78",
pages = "12--19",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "1",

}

TY - JOUR

T1 - Vessel bioengineering - Development of small-diameter arterial grafts -

AU - Tara, Shuhei

AU - Rocco, Kevin A.

AU - Hibino, Narutoshi

AU - Sugiura, Tadahisa

AU - Kurobe, Hirotsugu

AU - Breuer, Christopher K.

AU - Shinoka, Toshiharu

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The development of vascular bioengineering has led to a variety of novel treatment strategies for patients with cardiovascular isease. Notably, combining biodegradable scaffolds with autologous cell seeding to create tissue-engineered ascular grafts (TEVG) allows for in situ formation of organized neovascular tissue and we have demonstrated he clinical viability of this technique in patients with congenital heart defects. The role of the scaffold is to rovide a temporary 3-dimensional structure for cells, but applying TEVG strategy to the arterial system requires caffolds that can also endure arterial pressure. Both biodegradable synthetic polymers and extracellular matrixbased atural materials can be used to generate arterial scaffolds that satisfy these requirements. Furthermore, the ole of specific cell types in tissue remodeling is crucial and as a result many different cell sources, from matured omatic cells to stem cells, are now used in a variety of arterial TEVG techniques. However, despite great progress n the field over the past decade, clinical effectiveness of small-diameter arterial TEVG (<6 mm) has remained elusive. o achieve successful translation of this complex multidisciplinary technology to the clinic, active participation f biologists, engineers, and clinicians is required.

AB - The development of vascular bioengineering has led to a variety of novel treatment strategies for patients with cardiovascular isease. Notably, combining biodegradable scaffolds with autologous cell seeding to create tissue-engineered ascular grafts (TEVG) allows for in situ formation of organized neovascular tissue and we have demonstrated he clinical viability of this technique in patients with congenital heart defects. The role of the scaffold is to rovide a temporary 3-dimensional structure for cells, but applying TEVG strategy to the arterial system requires caffolds that can also endure arterial pressure. Both biodegradable synthetic polymers and extracellular matrixbased atural materials can be used to generate arterial scaffolds that satisfy these requirements. Furthermore, the ole of specific cell types in tissue remodeling is crucial and as a result many different cell sources, from matured omatic cells to stem cells, are now used in a variety of arterial TEVG techniques. However, despite great progress n the field over the past decade, clinical effectiveness of small-diameter arterial TEVG (<6 mm) has remained elusive. o achieve successful translation of this complex multidisciplinary technology to the clinic, active participation f biologists, engineers, and clinicians is required.

KW - Cell seeding

KW - Coronary artery disease

KW - Scaffolds

KW - Small-diameter arterial grafts

KW - Tissue-engineered vascular grafts

UR - http://www.scopus.com/inward/record.url?scp=84891124484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891124484&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-13-1440

DO - 10.1253/circj.CJ-13-1440

M3 - Review article

C2 - 24334558

AN - SCOPUS:84891124484

VL - 78

SP - 12

EP - 19

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 1

ER -